FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1226-1229 April 29, 1993 Number 17 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Chronic idiopathic thrombocytopenic purpura is a destructive thrombocytopenia caused by an autoantibody. About 80 percent of patients with chronic idiopathic thrombocytopenic purpura have remissions after either corticosteroid therapy or splenectomy. Some patients with resistant disease respond to other agents, but a substantial group are refractory to therapy.

Methods We used combination chemotherapy to treat 10 patients with refractory immune thrombocytopenia. An average of 6.8 (range, 3 to 10) previous therapies, including corticosteroids and splenectomy, had been unsuccessful in these patients. The patients received from three to eight cycles of therapy consisting of cyclophosphamide and prednisone combined with either vincristine (one patient), vincristine and procarbazine (four patients), or etoposide (six patients, including one patient who received four cycles each containing procarbazine and etoposide).

Results Among the 10 patients, 6 had complete responses (platelet count, >180,000 per cubic millimeter); of these, 4 patients had responses that persisted for more than 11, 30, 54, or 126 months, 1 had a relapse 9 months after therapy but had a remission with further therapy and remained in remission for 48 months before dying of an unrelated illness, and another relapsed just before her fifth course of therapy. Two patients had partial responses (platelet count, >50,000 per cubic millimeter); the platelet counts in one remained stable for more than nine months after the end of therapy, and the other patient relapsed. The remaining two patients had no response. Complete responses were associated with a disappearance or marked decrease in the level of platelet-associated autoantibody.

Conclusions Combination chemotherapy is beneficial in some patients in whom immune thrombocytopenia is refractory to corticosteroids and splenectomy.

Source Information

From the Department of Molecular and Experimental Medicine, the Scripps Research Institute, 10666 N. Torrey Pines Rd., La Jolla, CA 92037, where reprint requests should be addressed to Dr. McMillan.

Full Text of this Article

Related Letters:

Immunization of Adults
Rothstein E. P., Bernstein H. H., Long S. S., Gluckman S. J., Krause D. S., Gardner P., Schaffner W.
Extract | Full Text  
N Engl J Med 1993; 329:1046-1048, Sep 30, 1993. Correspondence

This article has been cited by other articles:

• Burzynski, J. (2009). New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 66: S11-S21 [Abstract] [Full Text]  
• Ruggeri, M., Fortuna, S., Rodeghiero, F. (2008). Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. haematol 93: 98-103 [Abstract] [Full Text]  
• Boruchov, D. M., Gururangan, S., Driscoll, M. C., Bussel, J. B. (2007). Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 110: 3526-3531 [Abstract] [Full Text]  
• Cines, D. B., Bussel, J. B. (2005). How I treat idiopathic thrombocytopenic purpura (ITP). Blood 106: 2244-2251 [Full Text]  
• Stasi, R., Provan, D. (2004). Management of Immune Thrombocytopenic Purpura in Adults. Mayo Clin Proc. 79: 504-522 [Abstract]  
• Vesely, S. K., Perdue, J. J., Rizvi, M. A., Terrell, D. R., George, J. N. (2004). Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy: A Systematic Review. ANN INTERN MED 140: 112-120 [Abstract] [Full Text]  
• Cines, D. B., Bussel, J. B., McMillan, R. B., Zehnder, J. L. (2004). Congenital and Acquired Thrombocytopenia. ASH Education Book 2004: 390-406 [Abstract] [Full Text]  
• Kuwana, M., Okazaki, Y., Kaburaki, J., Kawakami, Y., Ikeda, Y. (2002). Spleen Is a Primary Site for Activation of Platelet-Reactive T and B Cells in Patients with Immune Thrombocytopenic Purpura. J. Immunol. 168: 3675-3682 [Abstract] [Full Text]  
• Cines, D. B., Blanchette, V. S. (2002). Immune Thrombocytopenic Purpura. NEJM 346: 995-1008 [Full Text]  
• Stasi, R., Pagano, A., Stipa, E., Amadori, S. (2001). Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98: 952-957 [Abstract] [Full Text]  
• McMillan, R. (2001). Long-Term Outcomes after Treatment for Refractory Immune Thrombocytopenic Purpura. NEJM 344: 1402-1403 [Full Text]  
• McCrae, K. R., Bussel, J. B., Mannucci, P. M., Remuzzi, G., Cines, D. B. (2001). Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. ASH Education Book 2001: 282-305 [Abstract] [Full Text]  
• Bussel, J. B., Kunicki, T. J., Michelson, A. D. (2000). Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. ASH Education Book 2000: 222-240 [Abstract] [Full Text]  
• Werth, V. P. (1997). Pulse Intravenous Cyclophosphamide for Treatment of Autoimmune Blistering Disease: Is There an Advantage Over Oral Routes?. Arch Dermatol 133: 229-230 [Abstract]  
• George, J. N., El-Harake, M. A., Raskob, G. E. (1994). Chronic Idiopathic Thrombocytopenic Purpura. NEJM 331: 1207-1211 [Full Text]  
• Andersen, J. C. (1994). Response of Resistant Idiopathic Thrombocytopenic Purpura to Pulsed High-Dose Dexamethasone Therapy. NEJM 330: 1560-1564 [Abstract] [Full Text]  
• Kao, N. L., Richmond, G. W., Figueroa, M., McMillan, R. (1993). Combination Chemotherapy for ITP. NEJM 329: 1046-1046 [Full Text]